tbuckley/cabot-search huggingface dataset:
RARE-03. CNS GERMINOMA WITH SYNCHRONOUS LESIONS IN THE SELLAR AND PINEAL REGIONS
Authors: Armen Simonyan, Anna Mikhaylova, Levan Lepsveridze, Maksim Semenov
Journal: Neuro-Oncology (2019)

Abstract Germinomas comprise approximately 2–5% of all CNS malignancies, and have a favourable prognosis. Bad outcomes are relatively rare. Synchronous lesions occurs in 5–10% of cases. We report a case of 28 years old male, presented with motor aphasia, visual impairment and dysphagia. In period of last 15 months patient underwent 3 surgical interventions due to occlusive hydrocephalus. MRI revealed volume formations of the pineal and sellar regions. Taking into account the severity of the patient’s condition, consilium decided to refrain from surgical intervention and adjuvant therapy. Patient was transferred to the palliative unit. He died after 3 months. According to the results of the autopsy, the histological changes in tumors of the pineal and infundibular regions, corresponds to the germinoma. Due to the lack of information about patient’s treatment, carried out until hospitalization in our center, we don’t undertake to judge whether there was diagnostic omission, or incorrect treatment in this clinical case. But in our opinion, in case of suspected CNS germinoma, it is necessary to conduct more “aggressive treatment” (Tumor biopsy, followed by radiotherapy and chemotherapy). Symptomatic treatment should be used in cases, where the treatment of main disease is impossible. We hope that this sad clinical case will help Neurosurgeons in making decisions in a difficult situation.
Epidermal Growth Factor Stimulates Exosomal microRNA-21 Derived from Mesenchymal Stem Cells to Ameliorate aGVHD By Modulating Regulatory T Cells
Authors: Minmin Chen, Haojie Zhu, Lingqiong Lan, Yuxin Zhang, Qiuru Chen, Yanling Zeng, Xiaofeng Luo, Jinhua Ren, Zhizhe Chen, Jianda Hu, Ting Yang
Journal: Blood (2019)
Physical Function, Pain Severity, and Fatigue in Patients with Relapsed/Refractory Multiple Myeloma: Health-Related Quality of Life Results in Patients Receiving Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone
Authors: Cristina Gasparetto, Rakesh Popat, Shaji K. Kumar, Michele Cavo, Javier de la Rubia, Vania T.M. Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, James Maciel, Liang-Tsai Hsiao, Philippe Moreau, Simon Harrison, Jia Jia, Sudeep Karve, Esprit Ma, Jacob Devine, Katy Benjamin
Journal: Blood (2019)
MRD Evaluation By PET/CT According to Deauville Criteria Combined with Multiparameter Flow Cytometry in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients Enrolled in the Phase II Randomized Forte Trial
Authors: Elena Zamagni, Cristina Nanni, Francesca Gay, Luca Dozza, Delia Rota Scalabrini, Paola Omedé, Rossella Ribolla, Monica Galli, Manuela Racca, Renato Zambello, Barbara Gamberi, Domenico Albano, Annibale Versari, Mariella Grasso, Rossella Troia, Tonino Spadano, Francesca Patriarca, Marina Ruggeri, Marco Rensi, Anna Pascarella, Pietro Zucchetta, Paola Tacchetti, Stefano Fanti, Mario Boccadoro, Michele Cavo, Stefania Oliva
Journal: Blood (2019)
Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens
Authors: Donna E Reece, Esther Masih-Khan, Eshetu G Atenafu, Victor Jimenez-Zepeda, Arleigh McCurdy, Kevin Song, Michael Sebag, Richard Leblanc, Martha L Louzada, Darrell J White, Julie Stakiw, Tony Reiman, Rami Kotb, Muhammad Aslam, Engin Gul, Christopher P Venner
Journal: Blood (2019)
A pH/ROS dual-responsive and targeting nanotherapy for vascular inflammatory diseases
Authors: Runjun Zhang, Renfeng Liu, Chao Liu, Lina Pan, Yuantong Qi, Juan Cheng, Jiawei Guo, Yi Jia, Jun Ding, Jianxiang Zhang, Houyuan Hu
Journal: Biomaterials (2019)

Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide. Vascular inflammation is closely related to the pathogenesis of a diverse group of CVDs. Currently, it remains a great challenge to achieve site-specific delivery and controlled release of therapeutics at vascular inflammatory sites. Herein we hypothesize that active targeting nanoparticles (NPs) simultaneously responsive to low pH and high levels of reactive oxygen species (ROS) can serve as an effective nanoplatform for precision delivery of therapeutic cargoes to the sites of vascular inflammation, in view of acidosis and oxidative stress at inflamed sites. The pH/ROS dual-responsive NPs were constructed by combination of a pH-sensitive material (ACD) and an oxidation-responsive material (OCD) that can be facilely synthesized by chemical functionalization of β-cyclodextrin, a cyclic oligosaccharide. Simply by regulating the weight ratio of ACD and OCD, the pH/ROS responsive capacity can be easily modulated, affording NPs with varied hydrolysis profiles under inflammatory microenvironment. Using rapamycin (RAP) as a candidate drug, we first demonstrated in vitro therapeutic advantages of RAP-containing NPs with optimal dual-responsive capability, i.e. RAP/AOCD NP, and a non-responsive nanotherapy (RAP/PLGA NP) and two single-responsive nanotherapies (RAP/ACD NP and RAP/OCD NP) were used as controls. In an animal model of vascular inflammation in rats subjected to balloon injury in carotid arteries, AOCD NP could accumulate at the diseased site after intravenous (i.v.) injection. Consistently, i. v. treatment with RAP/AOCD NP more effectively inhibited neointimal hyperplasia in rats with induced arterial injuries, compared to RAP/PLGA NP, RAP/ACD NP, and RAP/OCD NP. By surface decoration of AOCD NP with a peptide (KLWVLPKGGGC) targeting type IV collagen (Col-IV), the obtained Col-IV targeting, dual-responsive nanocarrier TAOCD NP showed dramatically increased accumulation at injured carotid arteries. Furthermore, RAP/TAOCD NP exhibited significantly potentiated in vivo efficacy in comparison to the passive targeting nanotherapy RAP/AOCD NP. Importantly, in vitro cell culture experiments and in vivo animal studies in both mice and rats revealed good safety for AOCD NP and RAP/AOCD NP, even after long-term treatment via i. v. injection. Consequently, our results demonstrated that the newly developed Col-IV targeting, pH/ROS dual-responsive NPs may serve as an effective and safe nanovehicle for precision therapy of arterial restenosis and other vascular inflammatory diseases.
CC-90009, a Novel Cereblon E3 Ligase Modulator, Targets GSPT1 for Degradation to Induce Potent Tumoricidal Activity Against Acute Myeloid Leukemia (AML)
Authors: Antonia Lopez-Girona, Gang Lu, Emily Rychak, Derek Mendy, Chin-Chun Lu, Irit Rappley, Celia Fontanillo, Brian E. Cathers, Thomas O. Daniel, Joshua Hansen
Journal: Blood (2019)
Predicting Risk of Kidney Disease
Authors: Sri Lekha Tummalapalli, Michelle M. Estrella
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PDTM-10. USE OF A NOVEL, HAND-HELD, ELECTRONIC DNA ANALYSIS PLATFORM TO QUANTIFY MULTI-GENE MOLECULAR RESPONSE IN CSF OF PATIENTS WITH HIGH-GRADE GLIOMA
Authors: Amy Bruzek, Leo Tunkle, Clarissa Babila, Ashwath Muruganand, Stefanie Stallard, Veena Thamilselvan, Tingting Qin, Ian Wolfe, Rajen Mody, Patricia Robertson, Cormac Maher, Karin Muraszko, Hugh Garton, Carl Koschmann
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND For midline tumors, surgical biopsy risks neurological injury. Non-invasive methods for diagnosis and surveillance are greatly needed. Tumors release DNA into cerebrospinal fluid (CSF-ctDNA), allowing for potential detection and serial monitoring of tumor-associated genetic mutations by CSF sampling. Current detection platforms are limited by their requirement for assay development for each mutation (digital droplet PCR), or cost and timeliness (Illumina sequencing). We hypothesized that direct, electronic analysis of CSF-ctDNA with a novel, hand-held platform (Oxford Nanopore MinION) could provide real-time, ultra-deep sequencing of patient-specific alterations in CSF-ctDNA. METHODS We established multiple clinical trials for pediatric high-grade glioma with required multi-time point (0, 2, and 6 month) correlate lumbar puncture (LP) at time of MRI, with accrual ongoing. We performed amplicon-based PCR on CSF-ctDNA for recurrent mutations and sequenced patient samples (tumor tissue n=8, tumor CSF n=60) and normal controls (tissue n=5, CSF n=24) using NanoPore technology. Variant allele fractions (VAF) were determined via MinKNOW, Guppy, MiniMap2, and Integrated Genome Browser. RESULTS Sensitivity was 79% and specificity 100% by NanoPore. Time from LP to results was 12 hours. A 17-year-old female presented with a biopsy-proven grade IV thalamic glioma with clonal mutations in H3F3A K27M, PIK3CA E545G, TP53 R158G, and TP53 R248Q. After failing standard treatment, she was enrolled in the ONC201 clinical trial and underwent serial LPs. MRI showed stable tumor at 2 months and 40% decrease at 6 months of treatment. H3K27M VAF increased from baseline at 2 months, but decreased to 1% at 6 months of treatment, results that were confirmed by ddPCR. PIK3CA E545G, TP53 R158G, and TP53 R248Q demonstrated the same decrease in VAF, with p-value of &lt; 0.0001. CONCLUSIONS We demonstrate a rapid, reliable method to detect tumor mutations in CSF, and further show molecular remission of H3K27M glioma by CSF sampling.
Ighv Mutational Status By Deep Next Generation Sequencing Refines Ighv Sanger Sequencing Classification in Patients with Chronic Lymphocytic Leukaemia
Authors: Azahara Fuentes, Alicia Serrano, Blanca Ferrer Lores, Veronica Lendinez, Carolina Monzo, Carmen Ivorra, Mar Tormo, Maria Jose Terol, Blanca Navarro, Javier F Chaves
Journal: Blood (2019)
CRISPR Dropout Screens Identify DHODH,PIK3C3, and Crkl as Potential Therapeutic Targets in Acute Myeloid Leukemia
Authors: Gregory Takacs, Yujia Zhou, David J. King, Amy Meacham, Loguinov Alex, Abderrahmane Tagmount, Amin Sobh, Max Russo, Chris D Vulpe, Christopher R. Cogle
Journal: Blood (2019)
An Analysis of Racial and Ethnic Backgrounds within the Casire International Cohort of Sickle Cell Disease Patients: Implications for Disease Phenotype and Clinical Research
Authors: Andrew D. Campbell, Raffaella Colombatti, Biree Andemariam, Crawford John Strunk, Immacolata Tartaglione, Connie M. Piccone, Deepa Manwani, Eugenia Vicky Asare, Fatimah Farooq, Rebekah Urbonya, Gifty Dankwah, Silverio Perrotta, Laura Sainati, Angela Rivers, Sudha Rao, William Zempsky, Fredericka Sey, Catherine Idara Segbefia, Baba PD Inusa, Charles Antwi-Boasiako
Journal: Blood (2019)
Comparison of Allogeneic Transplant Outcomes Using Conditioning with Different Dose of Busulfan for Children with Acute Myeloid Leukemia
Authors: Olesia V Paina, Zhemal Zarifovna Rakhmanova, Polina Valerievna Kozhokar, Anastasia S Frolova, Kirill Alexandrovich Ekushov, Luibov Tsvetkova, Tatiana A Bykova, Inna V Markova, Sergey N. Bondarenko, Ildar M Barkhatov, Aleksandr Alyanski, Elena Babenko, Ivan S Moiseev, Marina O Popova, Elena Vladimirovna Semenova, Ludmila S Zubarovskaya, Axel Zander, Boris Afanasyev
Journal: Blood (2019)
Oncogenic MAF in Co-Operation with IRF4 Confers Extensive Chromatin Re-Arrangement in Plasma Cells and Generates 'Neo-Enhancers' That Regulate Genes Critical for Myeloma Biology
Authors: Alexia Katsarou, Nikolaos Trasanidis, Jaime Alvarez-Benayas, Foteini Papaleonidopoulou, Keren Keren, Ioannis V. Kostopoulos, Kanagaraju Ponnusamy, Xiaolin Xiao, Niklas Feldhahn, Irene Roberts, Evdoxia Hatjiharissi, Maria Papaioannou, Ian Sudbery, Aristeidis Chaidos, Valentina S Caputo, Anastasios Karadimitris
Journal: Blood (2019)
Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis
Authors: Eytan M. Stein, Dominick Latremouille-Viau, George J Joseph, Sherry Shi, Annie Guerin, Eric Q Wu, Gaetano Bonifacio, Xiting Cao
Journal: Blood (2019)
Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance
Authors: Alberto J Arribas, Sara Napoli, Eugenio Gaudio, Luciano Cascione, Alessandra Di Veroli, Chiara Tarantelli, Filippo Spriano, Antonella Zucchetto, Francesca Maria Rossi, Andrea Rinaldi, Anastasios Stathis, Georg Stuessi, Valter Gattei, Gabriele Cruciani, Emanuele Zucca, Davide Rossi, Francesco Bertoni
Journal: Blood (2019)
Discovery of a Novel Dihydroorotate Dehydrogenase Inhibitor That Induces Differentiation and Overcomes Ara-C Resistance of Acute Myeloid Leukemia Cells
Authors: Satoshi Kitazawa, Yukiko Ishii, Keiko Makita-Suzuki, Koichi Saito, Kensuke Takayanagi, Hiromi Sugihara, Shun Matsuda, Takayuki Yamakawa, Yasuhiro Tsutsui, Tadashi Tanaka, Tomohisa Hatta, Tohru Natsume, Toru Kondo, Yuichi Ishikawa, Shinji Hagiwara, Hitoshi Kiyoi
Journal: Blood (2019)
AB0026 LARGE JOINT ARTHRITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS IS CHARACTERISED BY T CELL RATHER THAN B CELL ACCUMULATION
Authors: Francesca Faustini, Natalie Sippl, Karine Chemin, Iva Gunnarsson, Vivianne Malmström
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> Musculoskeletal involvement is a common clinical feature of systemic lupus erythematosus (SLE), that can be present either at the onset or in later disease course. SLE related arthritis is usually non-erosive and non-deforming as opposed to rheumatoid arthritis (RA). While RA synovial pathology has been extensively studied, little is known about the pathophysiology of arthritis in SLE. Objectives: to explore the cellular compartments in synovial fluid of SLE patients with arthritic manifestations. Methods: paired synovial fluid (SF) samples from large joint aspiration and peripheral blood samples (PBMC) obtained at the same time point from five SLE patients were analyzed by multicolor flow cytometry. The patients fulfilled the ACR 1982 classification criteria for SLE [1]. Clinical records were reviewed in order to exclude the presence of comorbidities such osteoarthritis or overlap with RA. Three different lineage-specific panels for B cells, T cells (cytotoxic and helper) were developed. <h3>Results:</h3> The overall frequency of CD4+ and CD8+ T cells was similar across the SF and PBMC samples. Among the CD4+ T cells, those co-expressing CCR4, showed a much higher frequency in the SF compared to the peripheral blood in 4 out of 5 patients (mean percentage 8.9±7.0% vs 2.1±1.6%, p=ns). In addition, in 4 out of 5 patients we could identify an increased frequency of CD4+ expressing CCR6+, a marker for Th17 cells in SF as compared to PBMC (mean percentage 35±16.6% vs 12.7±8.9%, respectively, p=ns). In all patients, a higher frequency of EOMES+ Granzyme A + CD4+ T cells was observed in SF when compared to PBMC (9.2±2.5% vs 4.5±2.5%, p=0.03). Moreover, in all patients, we could observe a higher proportion of regulatory T cells (FOXP3+/CD25+) in the SF (21.5±15.4% vs 8.4±7.8%, p=ns). No relevant differences were observed in the Th1 compartment (CXCR3+). CD19+ cells (B-lymphocytes) were scarcely present in the SF of SLE patients as opposed to the peripheral blood. <h3>Conclusion:</h3> Although SLE is usually considered to be a B cell driven disease, its common clinical features like arthritis could be driven in situ by T cells, namely subtypes of CD4+ (helper) cells such as TH17 cells and CD4+ T cells with cytotoxic profile. Further confirmation of the present findings is needed. <h3>Reference</h3> [1] Tan, E.M., et al., The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 1982. 25(11 <h3>Disclosure of Interests:</h3> Francesca Faustini Consultant for: I have participated to an advisoryborad for Pfizer Sweden in one occasion during 2018, Speakers bureau: I have been speaker for an internal education meeting for Novartis Sweden in one occasion during 2018, Natalie Sippl: None declared, Karine Chemin: None declared, Iva Gunnarsson: None declared, Vivianne Malmström: None declared
IMMU-22. TARGETING NON-CANONICAL FUNCTION OF IDO1 IN GLIOBLASTOMA IMMUNOTHERAPY
Authors: Lijie Zhai, April Bell, Jun Qian, Erik Ladomersky, Kristen Lauing, Derek Wainwright
Journal: Neuro-Oncology (2019)

Abstract Recent failure of immune checkpoint blockade, anti-PD-1 therapy in patients suffering recurrent glioblastoma (GBM) indicates that development of novel immunosuppressive mediator-targeted therapeutic strategy is critical for more effective immunotherapies against GBM. Indoleamine 2, 3-dioxygenase 1 (IDO1) has been shown to mediate tumor-induced immunosuppression through its tryptophan catabolic activity. Surprisingly, pharmacological IDO1 enzyme inhibitors have not demonstrated any survival benefit in cancer patients either mono-therapeutically or in combination with other therapies. Previously we confirmed that tumor IDO1 mRNA expression is significantly upregulated in GBM patients compared to those from patients with lower grades gliomas. Furthermore, knockdown of IDO1 in mouse GBM cells significantly increased mouse survival and decreased tumor infiltrating Tregs, but did not affect tumor local tryptophan catabolism. Consistently, inhibition of IDO1 enzymatic activity on GBM-bearing mice did not yield any survival benefit. These findings indicate that IDO1 may suppress immune response through a non-enzymatic pathway. To test this hypothesis, IDO1-deficient mouse GBM cells were created and modified to stably express either wild-type (WT) or enzyme-null IDO1. Syngeneic mice intracranially engrafted with both WT and enzyme-null IDO1 overexpressing GBM cells showed significantly increase of tumor infiltrating Tregs and decreased survival in comparison to mice engrafted with IDO1-deficient GBM cells. In contrast, no difference was observed between WT-IDO1 GBM and enzyme-null IDO1 GBM groups. Additionally, when co-cultured with splenic monocytes, both WT and enzyme-null IDO1 overexpressing GBM cells induced more mature macrophages than IDO1-deficient GBM cells. Taken together, our data strongly imply an enzyme independent pathway associated with IDO1-driven immunosuppression in mouse GBM. Validation of this novel mechanism on human GBM cells is ongoing. A soluble molecule has been identified as a potential mediator for the non-enzymatic function of IDO1. Results from this study will provide innovative strategies for IDO1-based immunotherapy against GBM.
CBMT-32. EGFR SUPPRESSES p53 FUNCTION THROUGH DNA-PKcs BINDING TO p53: NOVEL CROSSTALK BETWEEN EGFR AND TP53 IN GLIOBLASTOMA
Authors: Jie Ding, Xiaolong Li, Chen Zhang, Feng Gao, Shaofang Wu, Amanda Wasylishen, Keith Baggerly, Guillermina Lozano, Dimpy Koul, Alfred Yung
Journal: Neuro-Oncology (2019)

Abstract Comprehensive analysis of the TCGA Glioblastoma database has identified 3 prognostically relevant subgroups (Proneural, Classical and Mesenchymal). Interestingly, it has also revealed a near mutual exclusivity of EGFR amplification and TP53 mutations. There are only a few tumors with both amplified EGFR and mutant TP53. We decided to investigate the functional relationship between EGFR and TP53 relative to tumorigenesis and tumor proliferation. We selected from our molecularly characterized GSC bank a series of EGFR amplified+TP53wt/TP53mut lines for this study. Here we report that EGFR amplification overrides the effect of p53wt but co-regulates tumorigenesis with TP53R175H mutation. We show that CRISPR EGFR knockout in TP53wt cells leads to complete loss of cell growth suggesting that EGFR is essential for cell survival, providing growth signal and suppression of p53wt function. We further show that EGFR induces physical binding between p53wt and DNA-PKcs, which suppresses p53wt by inhibiting p53 phosphorylation at S15. The knockdown of DNA-PKcs restores p53wt anti-tumor function. In contrast, GSC262 harboring TP53R175H mutation is the only GSC that survives after EGFR knockout, suggesting that this specific mutation has a gain of function (GOF) to sustain growth without EGFR. This is confirmed by dual knockout of EGFR and TP53R175H showing no surviving cells. Further investigation shows both EGFR and p53R175H induce tumor glycolysis, the major energy metabolism and heightened growth signal for this group. We further show that EGFR mediated suppression of p53R175H is through DNA-PKcs binding to p53R175H and reduced S15 phosphorylation. Taken together, this study reveals 1) EGFR amplification is essential for tumor growth in TP53wt GSCs; 2) novel crosstalk between EGFR and p53 through DNA-PKcs. 3) EGFR suppresses p53wt function by providing the energy required for tumor growth through inducing glycolysis, and 4) TP53R175H is a GOF mutation that sustains life without EGFR by inducing glycolysis.
Role of Donor-Derived CD19.CAR-T Cells in Treating Patients That Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Cheng Zhang, Lei Gao, Yao Liu, Li Gao, Pei-Yan Kong, Jun Liu, Ruihao Huang, Ying-Ying Ma, Defu Zeng, Qing-Hui Xiong, Wei-Ling Mei, Jia Liu, Peng-Fei Jiang, Xun Ye, De-Ping Han, Wei Cao, Xi Zhang
Journal: Blood (2019)
AB8939, a Microtubule-Destabilizing Agent with Potential to Overcome Multidrug Resistance, Is Active across the Range (M0-M7) of Acute Myeloid Leukemia Subtypes
Authors: Armelle Goubard, Martine Humbert, Colin Mansfield, Olivier Hermine, Patrice Dubreuil, The AB8939 Study Group
Journal: Blood (2019)
Daratumumab Inhibits AML Metabolic Capacity and Tumor Growth through Inhibition of CD38 Mediated Mitochondrial Transfer from Bone Marrow Stromal Cells to Blasts in the Leukemic Microenvironment
Authors: Jayna J Mistry, Charlotte Hellmich, Jamie A Moore, Christopher R Marlein, Genevra Pillinger, Angela Collins, Kristian M Bowles, Stuart A Rushworth
Journal: Blood (2019)